Devyser today announced that One Lambda™ Devyser Accept cfDNA, its test for monitoring kidney transplant patients, can now also be used after heart and lung transplantation. The new…
On Tuesday, November 3 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its interim report for the third quarter of 2026. The report will be published earlier…
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan. The agreement covers the…
Devyser today announces the appointment of Torben Thölix as Chief Commercial Officer (CCO). Torben will lead Devyser's global commercial organization and join the executive management…
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed…
“As previously announced, the second quarter was weaker than expected. Sales were negatively impacted by a temporary inventory adjustment by our single largest distributor. Underlying…
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation (HSCT). Building on the proven…
On Monday, July 20 at 09:00 a.m. CEST, Devyser Diagnostics AB will host an online presentation of its Q2 2026 report (which will have been published earlier on July 20 at 07:30 a.m.…
Devyser Diagnostics AB (publ) (the “Company” or the “Group”) announces that its preliminary sales for the second quarter of 2026 are weaker than indicated by the information and…
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in Regione Basilicata, Italy, with a total value of SEK 8.9 million. The tender includes…
